Timing of hypoxia PET/CT imaging after 18F-fluoromisonidazole injection in non-small cell lung cancer patients

Positron emission tomography (PET)/computed tomography (CT) using the radiotracer 18F-Fluoromisonidazole (FMISO) has been widely employed to image tumour hypoxia and is of interest to help develop novel hypoxia modifiers and guide radiation treatment planning. Yet, the optimal post-injection (p.i.)...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Scientific reports Jg. 12; H. 1; S. 21746 - 8
Hauptverfasser: Bourigault, Pauline, Skwarski, Michael, Macpherson, Ruth E., Higgins, Geoff S., McGowan, Daniel R.
Format: Journal Article
Sprache:Englisch
Veröffentlicht: London Nature Publishing Group UK 16.12.2022
Nature Publishing Group
Nature Portfolio
Schlagworte:
631/67/1612
631/67/2321
692/4028/67/1612
692/4028/67/2321
692/700/1421/1771
Atovaquone
Carcinoma, Non-Small-Cell Lung - diagnostic imaging
Carcinoma, Non-Small-Cell Lung - drug therapy
Cell Hypoxia
Computed tomography
Correlation coefficient
Humanities and Social Sciences
Humans
Hypoxia
Hypoxia - diagnostic imaging
Injection
Lung cancer
Lung Neoplasms - diagnostic imaging
Lung Neoplasms - drug therapy
Misonidazole
multidisciplinary
Non-small cell lung carcinoma
Patients
Positron emission tomography
Positron Emission Tomography Computed Tomography
Positron-Emission Tomography - methods
Radioactive tracers
Radiopharmaceuticals
Science
Science (multidisciplinary)
Small cell lung carcinoma
Tomography
Tumors
ISSN:2045-2322, 2045-2322
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Abstract Positron emission tomography (PET)/computed tomography (CT) using the radiotracer 18F-Fluoromisonidazole (FMISO) has been widely employed to image tumour hypoxia and is of interest to help develop novel hypoxia modifiers and guide radiation treatment planning. Yet, the optimal post-injection (p.i.) timing of hypoxic imaging remains questionable. Therefore, we investigated the correlation between hypoxia-related quantitative values in FMISO-PET acquired at 2 and 4 h p.i. in patients with non-small cell lung cancer (NSCLC). Patients with resectable NSCLC participated in the ATOM clinical trial (NCT02628080) which investigated the hypoxia modifying effects of atovaquone. Two-hour and four-hour FMISO PET/CT images acquired at baseline and pre-surgery visits (n = 58) were compared. Cohort 1 (n = 14) received atovaquone treatment, while cohort 2 (n = 15) did not. Spearman’s rank correlation coefficients (ρ) assessed the relationship between hypoxia-related metrics, including standardised uptake value (SUV), tumour-to-blood ratio (TBR), and tumour hypoxic volume (HV) defined by voxels with TBR ≥ 1.4. As the primary imaging-related trial endpoint used to evaluate the action of atovaquone on tumour hypoxia in patients with NSCLC was change in tumour HV from baseline, this was also assessed in patients (n = 20) with sufficient baseline 2- and 4-h scan HV to reliably measure change (predefined as ≥ 1.5 mL). Tumours were divided into four subregions or distance categories: edge, outer, inner, and centre, using MATLAB. In tumours overall, strong correlation (P < 0.001) was observed for SUV max ρ = 0.87, SUV mean ρ = 0.91, TBR max ρ = 0.83 and TBR mean ρ = 0.81 between 2- and 4-h scans. Tumour HV was moderately correlated (P < 0.001) with ρ = 0.69 between 2- and 4-h scans. Yet, in tumour subregions, the correlation of HV decreased from the centre ρ = 0.71 to the edge ρ = 0.45 (P < 0.001). SUV, TBR, and HV values were consistently higher on 4-h scans than on 2-h scans, indicating better tracer-to-background contrast. For instance, for TBR max , the mean, median, and interquartile range were 1.9, 1.7, and 1.6–2.0 2-h p.i., and 2.6, 2.4, and 2.0–3.0 4-h p.i., respectively. Our results support that FMISO-PET scans should be performed at 4 h p.i. to evaluate tumour hypoxia in NSCLC. Trial registration: ClinicalTrials.gov, NCT02628080. Registered 11/12/2015, https://clinicaltrials.gov/ct2/show/NCT02628080 .
AbstractList Positron emission tomography (PET)/computed tomography (CT) using the radiotracer 18F-Fluoromisonidazole (FMISO) has been widely employed to image tumour hypoxia and is of interest to help develop novel hypoxia modifiers and guide radiation treatment planning. Yet, the optimal post-injection (p.i.) timing of hypoxic imaging remains questionable. Therefore, we investigated the correlation between hypoxia-related quantitative values in FMISO-PET acquired at 2 and 4 h p.i. in patients with non-small cell lung cancer (NSCLC). Patients with resectable NSCLC participated in the ATOM clinical trial (NCT02628080) which investigated the hypoxia modifying effects of atovaquone. Two-hour and four-hour FMISO PET/CT images acquired at baseline and pre-surgery visits (n = 58) were compared. Cohort 1 (n = 14) received atovaquone treatment, while cohort 2 (n = 15) did not. Spearman’s rank correlation coefficients (ρ) assessed the relationship between hypoxia-related metrics, including standardised uptake value (SUV), tumour-to-blood ratio (TBR), and tumour hypoxic volume (HV) defined by voxels with TBR ≥ 1.4. As the primary imaging-related trial endpoint used to evaluate the action of atovaquone on tumour hypoxia in patients with NSCLC was change in tumour HV from baseline, this was also assessed in patients (n = 20) with sufficient baseline 2- and 4-h scan HV to reliably measure change (predefined as ≥ 1.5 mL). Tumours were divided into four subregions or distance categories: edge, outer, inner, and centre, using MATLAB. In tumours overall, strong correlation (P < 0.001) was observed for SUV max ρ = 0.87, SUV mean ρ = 0.91, TBR max ρ = 0.83 and TBR mean ρ = 0.81 between 2- and 4-h scans. Tumour HV was moderately correlated (P < 0.001) with ρ = 0.69 between 2- and 4-h scans. Yet, in tumour subregions, the correlation of HV decreased from the centre ρ = 0.71 to the edge ρ = 0.45 (P < 0.001). SUV, TBR, and HV values were consistently higher on 4-h scans than on 2-h scans, indicating better tracer-to-background contrast. For instance, for TBR max , the mean, median, and interquartile range were 1.9, 1.7, and 1.6–2.0 2-h p.i., and 2.6, 2.4, and 2.0–3.0 4-h p.i., respectively. Our results support that FMISO-PET scans should be performed at 4 h p.i. to evaluate tumour hypoxia in NSCLC. Trial registration: ClinicalTrials.gov, NCT02628080. Registered 11/12/2015, https://clinicaltrials.gov/ct2/show/NCT02628080 .
Positron emission tomography (PET)/computed tomography (CT) using the radiotracer 18F-Fluoromisonidazole (FMISO) has been widely employed to image tumour hypoxia and is of interest to help develop novel hypoxia modifiers and guide radiation treatment planning. Yet, the optimal post-injection (p.i.) timing of hypoxic imaging remains questionable. Therefore, we investigated the correlation between hypoxia-related quantitative values in FMISO-PET acquired at 2 and 4 h p.i. in patients with non-small cell lung cancer (NSCLC). Patients with resectable NSCLC participated in the ATOM clinical trial (NCT02628080) which investigated the hypoxia modifying effects of atovaquone. Two-hour and four-hour FMISO PET/CT images acquired at baseline and pre-surgery visits (n = 58) were compared. Cohort 1 (n = 14) received atovaquone treatment, while cohort 2 (n = 15) did not. Spearman’s rank correlation coefficients (ρ) assessed the relationship between hypoxia-related metrics, including standardised uptake value (SUV), tumour-to-blood ratio (TBR), and tumour hypoxic volume (HV) defined by voxels with TBR ≥ 1.4. As the primary imaging-related trial endpoint used to evaluate the action of atovaquone on tumour hypoxia in patients with NSCLC was change in tumour HV from baseline, this was also assessed in patients (n = 20) with sufficient baseline 2- and 4-h scan HV to reliably measure change (predefined as ≥ 1.5 mL). Tumours were divided into four subregions or distance categories: edge, outer, inner, and centre, using MATLAB. In tumours overall, strong correlation (P < 0.001) was observed for SUVmax ρ = 0.87, SUVmean ρ = 0.91, TBRmax ρ = 0.83 and TBRmean ρ = 0.81 between 2- and 4-h scans. Tumour HV was moderately correlated (P < 0.001) with ρ = 0.69 between 2- and 4-h scans. Yet, in tumour subregions, the correlation of HV decreased from the centre ρ = 0.71 to the edge ρ = 0.45 (P < 0.001). SUV, TBR, and HV values were consistently higher on 4-h scans than on 2-h scans, indicating better tracer-to-background contrast. For instance, for TBRmax, the mean, median, and interquartile range were 1.9, 1.7, and 1.6–2.0 2-h p.i., and 2.6, 2.4, and 2.0–3.0 4-h p.i., respectively. Our results support that FMISO-PET scans should be performed at 4 h p.i. to evaluate tumour hypoxia in NSCLC. Trial registration: ClinicalTrials.gov, NCT02628080. Registered 11/12/2015, https://clinicaltrials.gov/ct2/show/NCT02628080.
Abstract Positron emission tomography (PET)/computed tomography (CT) using the radiotracer 18F-Fluoromisonidazole (FMISO) has been widely employed to image tumour hypoxia and is of interest to help develop novel hypoxia modifiers and guide radiation treatment planning. Yet, the optimal post-injection (p.i.) timing of hypoxic imaging remains questionable. Therefore, we investigated the correlation between hypoxia-related quantitative values in FMISO-PET acquired at 2 and 4 h p.i. in patients with non-small cell lung cancer (NSCLC). Patients with resectable NSCLC participated in the ATOM clinical trial (NCT02628080) which investigated the hypoxia modifying effects of atovaquone. Two-hour and four-hour FMISO PET/CT images acquired at baseline and pre-surgery visits (n = 58) were compared. Cohort 1 (n = 14) received atovaquone treatment, while cohort 2 (n = 15) did not. Spearman’s rank correlation coefficients (ρ) assessed the relationship between hypoxia-related metrics, including standardised uptake value (SUV), tumour-to-blood ratio (TBR), and tumour hypoxic volume (HV) defined by voxels with TBR ≥ 1.4. As the primary imaging-related trial endpoint used to evaluate the action of atovaquone on tumour hypoxia in patients with NSCLC was change in tumour HV from baseline, this was also assessed in patients (n = 20) with sufficient baseline 2- and 4-h scan HV to reliably measure change (predefined as ≥ 1.5 mL). Tumours were divided into four subregions or distance categories: edge, outer, inner, and centre, using MATLAB. In tumours overall, strong correlation (P < 0.001) was observed for SUVmax ρ = 0.87, SUVmean ρ = 0.91, TBRmax ρ = 0.83 and TBRmean ρ = 0.81 between 2- and 4-h scans. Tumour HV was moderately correlated (P < 0.001) with ρ = 0.69 between 2- and 4-h scans. Yet, in tumour subregions, the correlation of HV decreased from the centre ρ = 0.71 to the edge ρ = 0.45 (P < 0.001). SUV, TBR, and HV values were consistently higher on 4-h scans than on 2-h scans, indicating better tracer-to-background contrast. For instance, for TBRmax, the mean, median, and interquartile range were 1.9, 1.7, and 1.6–2.0 2-h p.i., and 2.6, 2.4, and 2.0–3.0 4-h p.i., respectively. Our results support that FMISO-PET scans should be performed at 4 h p.i. to evaluate tumour hypoxia in NSCLC. Trial registration: ClinicalTrials.gov, NCT02628080. Registered 11/12/2015, https://clinicaltrials.gov/ct2/show/NCT02628080 .
Positron emission tomography (PET)/computed tomography (CT) using the radiotracer 18F-Fluoromisonidazole (FMISO) has been widely employed to image tumour hypoxia and is of interest to help develop novel hypoxia modifiers and guide radiation treatment planning. Yet, the optimal post-injection (p.i.) timing of hypoxic imaging remains questionable. Therefore, we investigated the correlation between hypoxia-related quantitative values in FMISO-PET acquired at 2 and 4 h p.i. in patients with non-small cell lung cancer (NSCLC). Patients with resectable NSCLC participated in the ATOM clinical trial (NCT02628080) which investigated the hypoxia modifying effects of atovaquone. Two-hour and four-hour FMISO PET/CT images acquired at baseline and pre-surgery visits (n = 58) were compared. Cohort 1 (n = 14) received atovaquone treatment, while cohort 2 (n = 15) did not. Spearman’s rank correlation coefficients (ρ) assessed the relationship between hypoxia-related metrics, including standardised uptake value (SUV), tumour-to-blood ratio (TBR), and tumour hypoxic volume (HV) defined by voxels with TBR ≥ 1.4. As the primary imaging-related trial endpoint used to evaluate the action of atovaquone on tumour hypoxia in patients with NSCLC was change in tumour HV from baseline, this was also assessed in patients (n = 20) with sufficient baseline 2- and 4-h scan HV to reliably measure change (predefined as ≥ 1.5 mL). Tumours were divided into four subregions or distance categories: edge, outer, inner, and centre, using MATLAB. In tumours overall, strong correlation (P < 0.001) was observed for SUVmax ρ = 0.87, SUVmean ρ = 0.91, TBRmax ρ = 0.83 and TBRmean ρ = 0.81 between 2- and 4-h scans. Tumour HV was moderately correlated (P < 0.001) with ρ = 0.69 between 2- and 4-h scans. Yet, in tumour subregions, the correlation of HV decreased from the centre ρ = 0.71 to the edge ρ = 0.45 (P < 0.001). SUV, TBR, and HV values were consistently higher on 4-h scans than on 2-h scans, indicating better tracer-to-background contrast. For instance, for TBRmax, the mean, median, and interquartile range were 1.9, 1.7, and 1.6–2.0 2-h p.i., and 2.6, 2.4, and 2.0–3.0 4-h p.i., respectively. Our results support that FMISO-PET scans should be performed at 4 h p.i. to evaluate tumour hypoxia in NSCLC.Trial registration: ClinicalTrials.gov, NCT02628080. Registered 11/12/2015, https://clinicaltrials.gov/ct2/show/NCT02628080.
Positron emission tomography (PET)/computed tomography (CT) using the radiotracer 18F-Fluoromisonidazole (FMISO) has been widely employed to image tumour hypoxia and is of interest to help develop novel hypoxia modifiers and guide radiation treatment planning. Yet, the optimal post-injection (p.i.) timing of hypoxic imaging remains questionable. Therefore, we investigated the correlation between hypoxia-related quantitative values in FMISO-PET acquired at 2 and 4 h p.i. in patients with non-small cell lung cancer (NSCLC). Patients with resectable NSCLC participated in the ATOM clinical trial (NCT02628080) which investigated the hypoxia modifying effects of atovaquone. Two-hour and four-hour FMISO PET/CT images acquired at baseline and pre-surgery visits (n = 58) were compared. Cohort 1 (n = 14) received atovaquone treatment, while cohort 2 (n = 15) did not. Spearman's rank correlation coefficients (ρ) assessed the relationship between hypoxia-related metrics, including standardised uptake value (SUV), tumour-to-blood ratio (TBR), and tumour hypoxic volume (HV) defined by voxels with TBR ≥ 1.4. As the primary imaging-related trial endpoint used to evaluate the action of atovaquone on tumour hypoxia in patients with NSCLC was change in tumour HV from baseline, this was also assessed in patients (n = 20) with sufficient baseline 2- and 4-h scan HV to reliably measure change (predefined as ≥ 1.5 mL). Tumours were divided into four subregions or distance categories: edge, outer, inner, and centre, using MATLAB. In tumours overall, strong correlation (P < 0.001) was observed for SUV ρ = 0.87, SUV ρ = 0.91, TBR ρ = 0.83 and TBR ρ = 0.81 between 2- and 4-h scans. Tumour HV was moderately correlated (P < 0.001) with ρ = 0.69 between 2- and 4-h scans. Yet, in tumour subregions, the correlation of HV decreased from the centre ρ = 0.71 to the edge ρ = 0.45 (P < 0.001). SUV, TBR, and HV values were consistently higher on 4-h scans than on 2-h scans, indicating better tracer-to-background contrast. For instance, for TBR , the mean, median, and interquartile range were 1.9, 1.7, and 1.6-2.0 2-h p.i., and 2.6, 2.4, and 2.0-3.0 4-h p.i., respectively. Our results support that FMISO-PET scans should be performed at 4 h p.i. to evaluate tumour hypoxia in NSCLC.Trial registration: ClinicalTrials.gov, NCT02628080. Registered 11/12/2015, https://clinicaltrials.gov/ct2/show/NCT02628080 .
Positron emission tomography (PET)/computed tomography (CT) using the radiotracer 18F-Fluoromisonidazole (FMISO) has been widely employed to image tumour hypoxia and is of interest to help develop novel hypoxia modifiers and guide radiation treatment planning. Yet, the optimal post-injection (p.i.) timing of hypoxic imaging remains questionable. Therefore, we investigated the correlation between hypoxia-related quantitative values in FMISO-PET acquired at 2 and 4 h p.i. in patients with non-small cell lung cancer (NSCLC). Patients with resectable NSCLC participated in the ATOM clinical trial (NCT02628080) which investigated the hypoxia modifying effects of atovaquone. Two-hour and four-hour FMISO PET/CT images acquired at baseline and pre-surgery visits (n = 58) were compared. Cohort 1 (n = 14) received atovaquone treatment, while cohort 2 (n = 15) did not. Spearman's rank correlation coefficients (ρ) assessed the relationship between hypoxia-related metrics, including standardised uptake value (SUV), tumour-to-blood ratio (TBR), and tumour hypoxic volume (HV) defined by voxels with TBR ≥ 1.4. As the primary imaging-related trial endpoint used to evaluate the action of atovaquone on tumour hypoxia in patients with NSCLC was change in tumour HV from baseline, this was also assessed in patients (n = 20) with sufficient baseline 2- and 4-h scan HV to reliably measure change (predefined as ≥ 1.5 mL). Tumours were divided into four subregions or distance categories: edge, outer, inner, and centre, using MATLAB. In tumours overall, strong correlation (P < 0.001) was observed for SUVmax ρ = 0.87, SUVmean ρ = 0.91, TBRmax ρ = 0.83 and TBRmean ρ = 0.81 between 2- and 4-h scans. Tumour HV was moderately correlated (P < 0.001) with ρ = 0.69 between 2- and 4-h scans. Yet, in tumour subregions, the correlation of HV decreased from the centre ρ = 0.71 to the edge ρ = 0.45 (P < 0.001). SUV, TBR, and HV values were consistently higher on 4-h scans than on 2-h scans, indicating better tracer-to-background contrast. For instance, for TBRmax, the mean, median, and interquartile range were 1.9, 1.7, and 1.6-2.0 2-h p.i., and 2.6, 2.4, and 2.0-3.0 4-h p.i., respectively. Our results support that FMISO-PET scans should be performed at 4 h p.i. to evaluate tumour hypoxia in NSCLC.Trial registration: ClinicalTrials.gov, NCT02628080. Registered 11/12/2015, https://clinicaltrials.gov/ct2/show/NCT02628080 .Positron emission tomography (PET)/computed tomography (CT) using the radiotracer 18F-Fluoromisonidazole (FMISO) has been widely employed to image tumour hypoxia and is of interest to help develop novel hypoxia modifiers and guide radiation treatment planning. Yet, the optimal post-injection (p.i.) timing of hypoxic imaging remains questionable. Therefore, we investigated the correlation between hypoxia-related quantitative values in FMISO-PET acquired at 2 and 4 h p.i. in patients with non-small cell lung cancer (NSCLC). Patients with resectable NSCLC participated in the ATOM clinical trial (NCT02628080) which investigated the hypoxia modifying effects of atovaquone. Two-hour and four-hour FMISO PET/CT images acquired at baseline and pre-surgery visits (n = 58) were compared. Cohort 1 (n = 14) received atovaquone treatment, while cohort 2 (n = 15) did not. Spearman's rank correlation coefficients (ρ) assessed the relationship between hypoxia-related metrics, including standardised uptake value (SUV), tumour-to-blood ratio (TBR), and tumour hypoxic volume (HV) defined by voxels with TBR ≥ 1.4. As the primary imaging-related trial endpoint used to evaluate the action of atovaquone on tumour hypoxia in patients with NSCLC was change in tumour HV from baseline, this was also assessed in patients (n = 20) with sufficient baseline 2- and 4-h scan HV to reliably measure change (predefined as ≥ 1.5 mL). Tumours were divided into four subregions or distance categories: edge, outer, inner, and centre, using MATLAB. In tumours overall, strong correlation (P < 0.001) was observed for SUVmax ρ = 0.87, SUVmean ρ = 0.91, TBRmax ρ = 0.83 and TBRmean ρ = 0.81 between 2- and 4-h scans. Tumour HV was moderately correlated (P < 0.001) with ρ = 0.69 between 2- and 4-h scans. Yet, in tumour subregions, the correlation of HV decreased from the centre ρ = 0.71 to the edge ρ = 0.45 (P < 0.001). SUV, TBR, and HV values were consistently higher on 4-h scans than on 2-h scans, indicating better tracer-to-background contrast. For instance, for TBRmax, the mean, median, and interquartile range were 1.9, 1.7, and 1.6-2.0 2-h p.i., and 2.6, 2.4, and 2.0-3.0 4-h p.i., respectively. Our results support that FMISO-PET scans should be performed at 4 h p.i. to evaluate tumour hypoxia in NSCLC.Trial registration: ClinicalTrials.gov, NCT02628080. Registered 11/12/2015, https://clinicaltrials.gov/ct2/show/NCT02628080 .
ArticleNumber 21746
Author Higgins, Geoff S.
Macpherson, Ruth E.
Skwarski, Michael
Bourigault, Pauline
McGowan, Daniel R.
Author_xml – sequence: 1
  givenname: Pauline
  surname: Bourigault
  fullname: Bourigault, Pauline
  organization: Department of Oncology, University of Oxford
– sequence: 2
  givenname: Michael
  surname: Skwarski
  fullname: Skwarski, Michael
  organization: Department of Oncology, University of Oxford, Department of Oncology, Oxford University Hospitals NHS Foundation Trust, Department of Clinical Oncology, Guy’s and St Thomas’ NHS Foundation Trust
– sequence: 3
  givenname: Ruth E.
  surname: Macpherson
  fullname: Macpherson, Ruth E.
  organization: Department of Radiology, Oxford University Hospitals NHS Foundation Trust
– sequence: 4
  givenname: Geoff S.
  surname: Higgins
  fullname: Higgins, Geoff S.
  organization: Department of Oncology, University of Oxford, Department of Oncology, Oxford University Hospitals NHS Foundation Trust
– sequence: 5
  givenname: Daniel R.
  surname: McGowan
  fullname: McGowan, Daniel R.
  email: daniel.mcgowan@oncology.ox.ac.uk
  organization: Department of Oncology, University of Oxford, Department of Medical Physics and Clinical Engineering, Oxford University Hospitals NHS Foundation Trust
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36526815$$D View this record in MEDLINE/PubMed
BookMark eNp9Ustu1DAUtVARLaU_wAJFYsMm1M_Y2SChUQuVKsFiWFuOc516lLEHO0GUr8czaaHtol7YV77nHJ37eI2OQgyA0FuCPxLM1HnmRLSqxpTWtCFtW8sX6IRiLmrKKD16EB-js5w3uBxBW07aV-iYNYI2iogTFNZ-68NQRVfd3O7ib2-q7xfr89W68lsz7DPGTZAqoi5rN84xxa3PMfje_IkjVD5swE4-hhJVxWGdt2YcKwvlGufCtibYQt-ZyUOY8hv00pkxw9nde4p-XF6sV1_r629frlafr2vb4GaqGwHEgYCuIcJKTrFhkjnsetW4vgMirXG8p7h1gJnEhCvZdEZZajjvuAJ2iq4W3T6ajd6lUky61dF4ffiIadAmTd6OoDFlylnZM-ko71zXQc860ioOxFgJomh9WrR2c7eF3pY6khkfiT7OBH-jh_hLt1IoQtoi8OFOIMWfM-RJlx7uW2QCxDlrKoUQUnGJC_T9E-gmzimUVh1QGLdl9gX17qGjf1bux1oAagHYFHNO4LT1k9nPqRj0oyZY75dIL0tUWkD1YYm0LFT6hHqv_iyJLaRcwGGA9N_2M6y_vl_aPg
CitedBy_id crossref_primary_10_1038_s41419_023_06405_8
crossref_primary_10_1016_j_ejmp_2024_104853
crossref_primary_10_1183_20734735_0176_2023
crossref_primary_10_3390_ijms26146679
crossref_primary_10_1053_j_semnuclmed_2024_10_001
crossref_primary_10_3389_fimmu_2025_1573039
crossref_primary_10_1097_PPO_0000000000000778
Cites_doi 10.1007/s11307-021-01580-6
10.1186/s13550-019-0525-6
10.1016/j.radonc.2010.10.011
10.1007/s00259-011-2037-0
10.1007/s00259-019-04626-8
10.1007/s11307-018-1214-y
10.1038/oncsis.2015.50
10.2967/jnumed.108.051326
10.1177/0271678X20923857
10.2967/jnumed.107.045914
10.1007/s00066-004-1229-y
10.1038/bjc.1981.79
10.1002/mp.12416
10.1007/s00259-002-1096-7
10.2967/jnumed.112.109330
10.1016/S0360-3016(96)00325-2
10.1158/1078-0432.CCR-20-4128
10.1038/sj.bjc.6602219
10.3413/nukmed-00328-10-07
10.1007/s00259-002-1037-5
10.1007/s00259-006-0175-6
10.2967/jnumed.112.118083
10.2967/jnumed.112.111963
10.1007/s00330-006-0431-y
10.1002/ijc.2910610422
10.1148/radiology.194.3.7862981
10.1016/0360-3016(89)90146-6
10.1007/s00259-010-1437-x
10.1016/S0969-8051(02)00442-0
10.1016/S0167-8140(03)00081-1
10.1016/j.ejca.2019.03.015
10.1038/nrc3064
10.1016/0360-3016(92)91001-4
10.3109/0284186X.2015.1067721
10.1667/0033-7587(2000)153[0084:DHFIAR]2.0.CO;2
10.1016/0006-2952(91)90245-Z
10.1186/s13550-021-00871-x
10.2967/jnumed.115.159301
ContentType Journal Article
Copyright The Author(s) 2022
2022. The Author(s).
The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2022
– notice: 2022. The Author(s).
– notice: The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88A
88E
88I
8FE
8FH
8FI
8FJ
8FK
ABUWG
AEUYN
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M1P
M2P
M7P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOA
DOI 10.1038/s41598-022-26199-7
DatabaseName Springer Nature OA/Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Biology Database (Alumni Edition)
Medical Database (Alumni Edition)
Science Database (Alumni Edition)
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni Edition)
ProQuest One Sustainability
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
ProQuest Biological Science Collection
Health & Medical Collection (Alumni Edition)
Medical Database
Science Database
Biological Science Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Biology Journals (Alumni Edition)
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Science Journals (Alumni Edition)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest Science Journals
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList


Publicly Available Content Database
CrossRef
MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals (DOAJ)
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: PIMPY
  name: Publicly Available Content Database
  url: http://search.proquest.com/publiccontent
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2045-2322
EndPage 8
ExternalDocumentID oai_doaj_org_article_0238fc7d37f24bfbbed3b1984e1ac7e5
PMC9758119
36526815
10_1038_s41598_022_26199_7
Genre Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Research Trainees Coordinating Centre
  grantid: ICA-CL-2016-02-009
  funderid: http://dx.doi.org/10.13039/501100000659
– fundername: Howat Foundation
  grantid: C5255/A25069
  funderid: http://dx.doi.org/10.13039/501100016131
– fundername: Cancer Research UK
  grantid: C5255/A16466; C34326/A28684
  funderid: http://dx.doi.org/10.13039/501100000289
– fundername: Department of Health
– fundername: Cancer Research UK
  grantid: 28736
– fundername: Cancer Research UK
  grantid: 27515
– fundername: ;
  grantid: C5255/A16466; C34326/A28684
– fundername: ;
  grantid: ICA-CL-2016-02-009
– fundername: ;
  grantid: C5255/A25069
GroupedDBID 0R~
3V.
4.4
53G
5VS
7X7
88A
88E
88I
8FE
8FH
8FI
8FJ
AAFWJ
AAJSJ
AAKDD
ABDBF
ABUWG
ACGFS
ACSMW
ACUHS
ADBBV
ADRAZ
AENEX
AEUYN
AFKRA
AJTQC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
BVXVI
C6C
CCPQU
DIK
DWQXO
EBD
EBLON
EBS
ESX
FYUFA
GNUQQ
GROUPED_DOAJ
GX1
HCIFZ
HH5
HMCUK
HYE
KQ8
LK8
M0L
M1P
M2P
M48
M7P
M~E
NAO
OK1
PIMPY
PQQKQ
PROAC
PSQYO
RNT
RNTTT
RPM
SNYQT
UKHRP
AASML
AAYXX
AFFHD
AFPKN
CITATION
PHGZM
PHGZT
PJZUB
PPXIY
PQGLB
CGR
CUY
CVF
ECM
EIF
NPM
7XB
8FK
K9.
PKEHL
PQEST
PQUKI
PRINS
Q9U
7X8
PUEGO
5PM
ID FETCH-LOGICAL-c606t-65e1fe5eb615c7420a373f0fd86fdbe17caf4d209fe037014876ba8c2a44b48e3
IEDL.DBID DOA
ISICitedReferencesCount 7
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000934547900062&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 2045-2322
IngestDate Mon Nov 10 04:27:29 EST 2025
Tue Nov 04 02:07:11 EST 2025
Thu Sep 04 16:37:15 EDT 2025
Tue Oct 07 07:54:14 EDT 2025
Mon Jul 21 06:08:14 EDT 2025
Tue Nov 18 22:36:16 EST 2025
Sat Nov 29 02:07:42 EST 2025
Fri Feb 21 02:39:11 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License 2022. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c606t-65e1fe5eb615c7420a373f0fd86fdbe17caf4d209fe037014876ba8c2a44b48e3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://doaj.org/article/0238fc7d37f24bfbbed3b1984e1ac7e5
PMID 36526815
PQID 2755009038
PQPubID 2041939
PageCount 8
ParticipantIDs doaj_primary_oai_doaj_org_article_0238fc7d37f24bfbbed3b1984e1ac7e5
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9758119
proquest_miscellaneous_2755578470
proquest_journals_2755009038
pubmed_primary_36526815
crossref_citationtrail_10_1038_s41598_022_26199_7
crossref_primary_10_1038_s41598_022_26199_7
springer_journals_10_1038_s41598_022_26199_7
PublicationCentury 2000
PublicationDate 2022-12-16
PublicationDateYYYYMMDD 2022-12-16
PublicationDate_xml – month: 12
  year: 2022
  text: 2022-12-16
  day: 16
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Scientific reports
PublicationTitleAbbrev Sci Rep
PublicationTitleAlternate Sci Rep
PublicationYear 2022
Publisher Nature Publishing Group UK
Nature Publishing Group
Nature Portfolio
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
– name: Nature Portfolio
References Bentzen (CR19) 2003; 67
Abolmaali (CR31) 2011; 50
Thureau, Modzelewski (CR28) 2013; 54
Yang (CR10) 1995; 194
Chapman, Franko, Sharplin (CR3) 1981; 43
Imam (CR15) 2010; 25
Gagel, DiMartino (CR17) 2004; 180
Valk (CR7) 1992; 33
Zimny (CR18) 2006; 33
Okamoto (CR30) 2013; 54
Lewis, Dehdashti, Grigsby, Welch, Siegel (CR11) 2008; 49
Prekeges (CR26) 1991; 42
Padhani (CR16) 2007; 17
Koh (CR8) 1992; 22
Rasey (CR12) 1989; 17
Kobayashi (CR27) 2020; 47
McGowan (CR38) 2017; 44
Dubois, Haustermans (CR20) 2004; 91
Gross (CR4) 1995; 61
Rasey (CR14) 1996; 36
Cheng (CR22) 2013; 54
Kawamura (CR32) 2021; 23
Little (CR35) 2021; 41
Watanabe (CR42) 2019; 9
Bourigault (CR34) 2021; 11
McGowan (CR37) 2019; 113
Sorger (CR6) 2003; 30
Vera (CR29) 2011; 98
Rasey, Hofstrand, Muzi, Graham, Chin (CR13) 2000; 153
Ziemer (CR5) 2003; 30
Krohn, Link, Mason (CR25) 2008; 49
van Loon (CR9) 2010; 37
Shimizu (CR41) 2019; 21
Wack (CR40) 2015; 54
Wilson, Hay (CR1) 2011; 11
Eales, Hollinshead, Tennant (CR2) 2016; 5
Cherk (CR21) 2006; 47
Skwarski (CR33) 2021; 27
Teoh (CR36) 2015; 56
Rajendran (CR24) 2003; 30
Vaupel, Kallinowski, Okunieff (CR39) 1989; 49
Hirata (CR23) 2012; 39
PE Valk (26199_CR7) 1992; 33
S Watanabe (26199_CR42) 2019; 9
WJ Koh (26199_CR8) 1992; 22
P Vera (26199_CR29) 2011; 98
S Okamoto (26199_CR30) 2013; 54
DJ Yang (26199_CR10) 1995; 194
SK Imam (26199_CR15) 2010; 25
M Kawamura (26199_CR32) 2021; 23
P Vaupel (26199_CR39) 1989; 49
JSCJ Rasey (26199_CR13) 2000; 153
K Hirata (26199_CR23) 2012; 39
M Zimny (26199_CR18) 2006; 33
KA Krohn (26199_CR25) 2008; 49
M Skwarski (26199_CR33) 2021; 27
SC-RP Thureau (26199_CR28) 2013; 54
Y Shimizu (26199_CR41) 2019; 21
J van Loon (26199_CR9) 2010; 37
LLW Dubois (26199_CR20) 2004; 91
PV Little (26199_CR35) 2021; 41
P Bourigault (26199_CR34) 2021; 11
LS Ziemer (26199_CR5) 2003; 30
JG Rajendran (26199_CR24) 2003; 30
LJ Wack (26199_CR40) 2015; 54
D Sorger (26199_CR6) 2003; 30
JS Rasey (26199_CR14) 1996; 36
K Kobayashi (26199_CR27) 2020; 47
KL Eales (26199_CR2) 2016; 5
N Abolmaali (26199_CR31) 2011; 50
MW Gross (26199_CR4) 1995; 61
AR Padhani (26199_CR16) 2007; 17
EJ Teoh (26199_CR36) 2015; 56
BRP Gagel (26199_CR17) 2004; 180
DR McGowan (26199_CR37) 2019; 113
JS Rasey (26199_CR12) 1989; 17
J Cheng (26199_CR22) 2013; 54
JD Chapman (26199_CR3) 1981; 43
WR Wilson (26199_CR1) 2011; 11
DR McGowan (26199_CR38) 2017; 44
JSLR Lewis (26199_CR11) 2008; 49
L Bentzen (26199_CR19) 2003; 67
MH Cherk (26199_CR21) 2006; 47
JL Prekeges (26199_CR26) 1991; 42
References_xml – volume: 23
  start-page: 597
  issue: 4
  year: 2021
  end-page: 603
  ident: CR32
  article-title: Evaluation of optimal post-injection timing of hypoxic imaging with (18)F-fluoromisonidazole-PET/CT
  publication-title: Mol. Imaging Biol.
  doi: 10.1007/s11307-021-01580-6
– volume: 9
  start-page: 60
  issue: 1
  year: 2019
  ident: CR42
  article-title: Biodistribution and radiation dosimetry of the novel hypoxia PET probe [(18)F]DiFA and comparison with [(18)F]FMISO
  publication-title: EJNMMI Res.
  doi: 10.1186/s13550-019-0525-6
– volume: 98
  start-page: 109
  issue: 1
  year: 2011
  end-page: 116
  ident: CR29
  article-title: Simultaneous positron emission tomography (PET) assessment of metabolism with F-fluoro-2-deoxy-d-glucose (FDG), proliferation with F-fluoro-thymidine (FLT), and hypoxia with fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): A pilot study
  publication-title: Radiother. Oncol.
  doi: 10.1016/j.radonc.2010.10.011
– volume: 39
  start-page: 760
  issue: 5
  year: 2012
  end-page: 770
  ident: CR23
  article-title: F-Fluoromisonidazole positron emission tomography may differentiate glioblastoma multiforme from less malignant gliomas
  publication-title: Eur. J. Nucl. Med. Mol. Imaging
  doi: 10.1007/s00259-011-2037-0
– volume: 47
  start-page: 1833
  issue: 8
  year: 2020
  end-page: 1842
  ident: CR27
  article-title: Influence of the scan time point when assessing hypoxia in (18)F-fluoromisonidazole PET: 2 vs 4 h
  publication-title: Eur. J. Nucl. Med. Mol. Imaging
  doi: 10.1007/s00259-019-04626-8
– volume: 25
  start-page: 365
  issue: 3
  year: 2010
  end-page: 374
  ident: CR15
  article-title: Review of positron emission tomography tracers for imaging of tumor hypoxia
  publication-title: Cancer Biother. Radiopharm.
– volume: 21
  start-page: 122
  issue: 1
  year: 2019
  end-page: 129
  ident: CR41
  article-title: A Novel PET Probe "[(18)F]DiFA" accumulates in hypoxic region via glutathione conjugation following reductive metabolism
  publication-title: Mol. Imaging Biol.
  doi: 10.1007/s11307-018-1214-y
– volume: 5
  issue: 1
  year: 2016
  ident: CR2
  article-title: Hypoxia and metabolic adaptation of cancer cells
  publication-title: Oncogenesis
  doi: 10.1038/oncsis.2015.50
– volume: 49
  start-page: 1177
  year: 2008
  end-page: 1182
  ident: CR11
  article-title: An imaging comparison of 64Cu-ATSM and 60Cu-ATSM in cancer of the uterine cervix
  publication-title: J. Nucl. Med.
  doi: 10.2967/jnumed.108.051326
– volume: 41
  start-page: 617
  issue: 3
  year: 2021
  end-page: 629
  ident: CR35
  article-title: The cellular basis of increased PET hypoxia tracer uptake in focal cerebral ischemia with comparison between [(18)F]FMISO and [(64)Cu]CuATSM
  publication-title: J. Cereb. Blood Flow Metab.
  doi: 10.1177/0271678X20923857
– volume: 49
  start-page: 129s
  issue: Suppl 2
  year: 2008
  end-page: s148
  ident: CR25
  article-title: Molecular imaging of hypoxia
  publication-title: J. Nucl. Med.
  doi: 10.2967/jnumed.107.045914
– volume: 180
  start-page: 616
  year: 2004
  end-page: 622
  ident: CR17
  article-title: pO polarography versus positron emission tomography ([18F] fluoromisonidazole, [18F]-2-fluoro-2’-deoxyglucose)
  publication-title: Strahlenther. Onkol.
  doi: 10.1007/s00066-004-1229-y
– volume: 43
  start-page: 546
  issue: 4
  year: 1981
  end-page: 550
  ident: CR3
  article-title: A marker for hypoxic cells in tumours with potential clinical applicability
  publication-title: Br. J. Cancer
  doi: 10.1038/bjc.1981.79
– volume: 44
  start-page: 4665
  issue: 9
  year: 2017
  end-page: 4676
  ident: CR38
  article-title: (18) F-fluoromisonidazole uptake in advanced stage non-small cell lung cancer: A voxel-by-voxel PET kinetics study
  publication-title: Med. Phys.
  doi: 10.1002/mp.12416
– volume: 33
  start-page: 2133
  issue: 12
  year: 1992
  end-page: 2137
  ident: CR7
  article-title: Hypoxia in human gliomas: Demonstration by PET with fluorine-18-fluoromisonidazole
  publication-title: J. Nucl. Med.
– volume: 30
  start-page: 695
  issue: 5
  year: 2003
  end-page: 704
  ident: CR24
  article-title: [(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: Correlation of hypoxia, metabolism and VEGF expression
  publication-title: Eur. J. Nucl. Med. Mol. Imaging
  doi: 10.1007/s00259-002-1096-7
– volume: 54
  start-page: 201
  issue: 2
  year: 2013
  end-page: 207
  ident: CR30
  article-title: High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer
  publication-title: J. Nucl. Med.
  doi: 10.2967/jnumed.112.109330
– volume: 36
  start-page: 417
  issue: 2
  year: 1996
  end-page: 428
  ident: CR14
  article-title: Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: A pretherapy study of 37 patients
  publication-title: Int. J. Radiat. Oncol. Biol. Phys.
  doi: 10.1016/S0360-3016(96)00325-2
– volume: 27
  start-page: 2459
  issue: 9
  year: 2021
  end-page: 2469
  ident: CR33
  article-title: Mitochondrial inhibitor atovaquone increases tumor oxygenation and inhibits hypoxic gene expression in patients with non-small cell lung cancer
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-20-4128
– volume: 91
  start-page: 1947
  year: 2004
  end-page: 1954
  ident: CR20
  article-title: Evaluation of hypoxia in an experimental rat tumour model by [18F]Fluoromisonidazole PET and immunohistochemistry
  publication-title: Br. J. Cancer.
  doi: 10.1038/sj.bjc.6602219
– volume: 50
  start-page: 22
  issue: 1
  year: 2011
  end-page: 7
  ident: CR31
  article-title: Two or four hour [ F]FMISO-PET in HNSCC. When is the contrast best?
  publication-title: Nuklearmedizin
  doi: 10.3413/nukmed-00328-10-07
– volume: 30
  start-page: 259
  issue: 2
  year: 2003
  end-page: 266
  ident: CR5
  article-title: Noninvasive imaging of tumor hypoxia in rats using the 2-nitroimidazole 18F-EF5
  publication-title: Eur. J. Nucl. Med. Mol. Imaging
  doi: 10.1007/s00259-002-1037-5
– volume: 47
  start-page: 1921
  issue: 12
  year: 2006
  end-page: 1926
  ident: CR21
  article-title: Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F-Fluoromisonidazole and 18F-FDG PET
  publication-title: J. Nucl. Med.
– volume: 33
  start-page: 1426
  issue: 12
  year: 2006
  end-page: 1431
  ident: CR18
  article-title: FDG—A marker of tumour hypoxia? A comparison with [18F]fluoromisonidazole and pO -polarography in metastatic head and neck cancer
  publication-title: Eur. J. Nucl. Med. Mol. Imaging
  doi: 10.1007/s00259-006-0175-6
– volume: 54
  start-page: 1543
  year: 2013
  end-page: 50
  ident: CR28
  article-title: Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3′-deoxy-3′-18F-fluorothymidine PET images in lung cancer
  publication-title: J. Nucl. Med.
  doi: 10.2967/jnumed.112.118083
– volume: 54
  start-page: 333
  issue: 3
  year: 2013
  end-page: 340
  ident: CR22
  article-title: 18F-fluoromisonidazole PET/CT: A potential tool for predicting primary endocrine therapy resistance in breast cancer
  publication-title: J. Nucl. Med.
  doi: 10.2967/jnumed.112.111963
– volume: 17
  start-page: 861
  issue: 4
  year: 2007
  end-page: 872
  ident: CR16
  article-title: Imaging oxygenation of human tumours
  publication-title: Eur. Radiol.
  doi: 10.1007/s00330-006-0431-y
– volume: 49
  start-page: 6449
  issue: 23
  year: 1989
  end-page: 6465
  ident: CR39
  article-title: Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: A review
  publication-title: Cancer Res.
– volume: 61
  start-page: 567
  issue: 4
  year: 1995
  end-page: 573
  ident: CR4
  article-title: Calibration of misonidazole labeling by simultaneous measurement of oxygen tension and labeling density in multicellular spheroids
  publication-title: Int. J. Cancer
  doi: 10.1002/ijc.2910610422
– volume: 194
  start-page: 795
  issue: 3
  year: 1995
  end-page: 800
  ident: CR10
  article-title: Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia
  publication-title: Radiology
  doi: 10.1148/radiology.194.3.7862981
– volume: 17
  start-page: 985
  issue: 5
  year: 1989
  end-page: 991
  ident: CR12
  article-title: Radiolabelled fluoromisonidazole as an imaging agent for tumor hypoxia
  publication-title: Int. J. Radiat. Oncol. Biol. Phys.
  doi: 10.1016/0360-3016(89)90146-6
– volume: 37
  start-page: 1663
  issue: 9
  year: 2010
  end-page: 1668
  ident: CR9
  article-title: PET imaging of hypoxia using [18F]HX4: A phase I trial
  publication-title: Eur. J. Nucl. Med. Mol. Imaging
  doi: 10.1007/s00259-010-1437-x
– volume: 30
  start-page: 317
  issue: 3
  year: 2003
  end-page: 326
  ident: CR6
  article-title: [18F]Fluoroazomycinarabinofuranoside (18FAZA) and [18F]Fluoromisonidazole (18FMISO): A comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors
  publication-title: Nucl. Med. Biol.
  doi: 10.1016/S0969-8051(02)00442-0
– volume: 67
  start-page: 339
  issue: 3
  year: 2003
  end-page: 344
  ident: CR19
  article-title: Tumour oxygenation assessed by 18F-fluoromisonidazole PET and polarographic needle electrodes in human soft tissue tumours
  publication-title: Radiother. Oncol.
  doi: 10.1016/S0167-8140(03)00081-1
– volume: 113
  start-page: 87
  year: 2019
  end-page: 95
  ident: CR37
  article-title: Buparlisib with thoracic radiotherapy and its effect on tumour hypoxia: A phase I study in patients with advanced non-small cell lung carcinoma
  publication-title: Eur. J. Cancer
  doi: 10.1016/j.ejca.2019.03.015
– volume: 11
  start-page: 393
  issue: 6
  year: 2011
  end-page: 410
  ident: CR1
  article-title: Targeting hypoxia in cancer therapy
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc3064
– volume: 22
  start-page: 199
  issue: 1
  year: 1992
  end-page: 212
  ident: CR8
  article-title: Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole
  publication-title: Int. J. Radiat. Oncol. Biol. Phys.
  doi: 10.1016/0360-3016(92)91001-4
– volume: 54
  start-page: 1370
  issue: 9
  year: 2015
  end-page: 1377
  ident: CR40
  article-title: Comparison of [18F]-FMISO, [18F]-FAZA and [18F]-HX4 for PET imaging of hypoxia—A simulation study
  publication-title: Acta Oncol.
  doi: 10.3109/0284186X.2015.1067721
– volume: 153
  start-page: 84
  year: 2000
  end-page: 92
  ident: CR13
  article-title: Determining hypoxic fraction in a rat glioma by uptake of radiolabeled fluoromisonidazole
  publication-title: Radiat. Res.
  doi: 10.1667/0033-7587(2000)153[0084:DHFIAR]2.0.CO;2
– volume: 42
  start-page: 2387
  issue: 12
  year: 1991
  end-page: 2395
  ident: CR26
  article-title: Reduction of fluoromisonidazole, a new imaging agent for hypoxia
  publication-title: Biochem. Pharmacol.
  doi: 10.1016/0006-2952(91)90245-Z
– volume: 11
  start-page: 130
  issue: 1
  year: 2021
  ident: CR34
  article-title: Investigation of atovaquone-induced spatial changes in tumour hypoxia assessed by hypoxia PET/CT in non-small cell lung cancer patients
  publication-title: EJNMMI Res.
  doi: 10.1186/s13550-021-00871-x
– volume: 56
  start-page: 1447
  issue: 9
  year: 2015
  end-page: 52
  ident: CR36
  article-title: Phantom and clinical evaluation of the bayesian penalized likelihood reconstruction algorithm Q.Clear on an LYSO PET/CT system
  publication-title: J. Nucl. Med.
  doi: 10.2967/jnumed.115.159301
– volume: 30
  start-page: 259
  issue: 2
  year: 2003
  ident: 26199_CR5
  publication-title: Eur. J. Nucl. Med. Mol. Imaging
  doi: 10.1007/s00259-002-1037-5
– volume: 39
  start-page: 760
  issue: 5
  year: 2012
  ident: 26199_CR23
  publication-title: Eur. J. Nucl. Med. Mol. Imaging
  doi: 10.1007/s00259-011-2037-0
– volume: 91
  start-page: 1947
  year: 2004
  ident: 26199_CR20
  publication-title: Br. J. Cancer.
  doi: 10.1038/sj.bjc.6602219
– volume: 47
  start-page: 1833
  issue: 8
  year: 2020
  ident: 26199_CR27
  publication-title: Eur. J. Nucl. Med. Mol. Imaging
  doi: 10.1007/s00259-019-04626-8
– volume: 43
  start-page: 546
  issue: 4
  year: 1981
  ident: 26199_CR3
  publication-title: Br. J. Cancer
  doi: 10.1038/bjc.1981.79
– volume: 61
  start-page: 567
  issue: 4
  year: 1995
  ident: 26199_CR4
  publication-title: Int. J. Cancer
  doi: 10.1002/ijc.2910610422
– volume: 9
  start-page: 60
  issue: 1
  year: 2019
  ident: 26199_CR42
  publication-title: EJNMMI Res.
  doi: 10.1186/s13550-019-0525-6
– volume: 30
  start-page: 317
  issue: 3
  year: 2003
  ident: 26199_CR6
  publication-title: Nucl. Med. Biol.
  doi: 10.1016/S0969-8051(02)00442-0
– volume: 56
  start-page: 1447
  issue: 9
  year: 2015
  ident: 26199_CR36
  publication-title: J. Nucl. Med.
  doi: 10.2967/jnumed.115.159301
– volume: 5
  issue: 1
  year: 2016
  ident: 26199_CR2
  publication-title: Oncogenesis
  doi: 10.1038/oncsis.2015.50
– volume: 17
  start-page: 861
  issue: 4
  year: 2007
  ident: 26199_CR16
  publication-title: Eur. Radiol.
  doi: 10.1007/s00330-006-0431-y
– volume: 21
  start-page: 122
  issue: 1
  year: 2019
  ident: 26199_CR41
  publication-title: Mol. Imaging Biol.
  doi: 10.1007/s11307-018-1214-y
– volume: 153
  start-page: 84
  year: 2000
  ident: 26199_CR13
  publication-title: Radiat. Res.
  doi: 10.1667/0033-7587(2000)153[0084:DHFIAR]2.0.CO;2
– volume: 67
  start-page: 339
  issue: 3
  year: 2003
  ident: 26199_CR19
  publication-title: Radiother. Oncol.
  doi: 10.1016/S0167-8140(03)00081-1
– volume: 194
  start-page: 795
  issue: 3
  year: 1995
  ident: 26199_CR10
  publication-title: Radiology
  doi: 10.1148/radiology.194.3.7862981
– volume: 49
  start-page: 1177
  year: 2008
  ident: 26199_CR11
  publication-title: J. Nucl. Med.
  doi: 10.2967/jnumed.108.051326
– volume: 47
  start-page: 1921
  issue: 12
  year: 2006
  ident: 26199_CR21
  publication-title: J. Nucl. Med.
– volume: 42
  start-page: 2387
  issue: 12
  year: 1991
  ident: 26199_CR26
  publication-title: Biochem. Pharmacol.
  doi: 10.1016/0006-2952(91)90245-Z
– volume: 37
  start-page: 1663
  issue: 9
  year: 2010
  ident: 26199_CR9
  publication-title: Eur. J. Nucl. Med. Mol. Imaging
  doi: 10.1007/s00259-010-1437-x
– volume: 33
  start-page: 1426
  issue: 12
  year: 2006
  ident: 26199_CR18
  publication-title: Eur. J. Nucl. Med. Mol. Imaging
  doi: 10.1007/s00259-006-0175-6
– volume: 113
  start-page: 87
  year: 2019
  ident: 26199_CR37
  publication-title: Eur. J. Cancer
  doi: 10.1016/j.ejca.2019.03.015
– volume: 44
  start-page: 4665
  issue: 9
  year: 2017
  ident: 26199_CR38
  publication-title: Med. Phys.
  doi: 10.1002/mp.12416
– volume: 23
  start-page: 597
  issue: 4
  year: 2021
  ident: 26199_CR32
  publication-title: Mol. Imaging Biol.
  doi: 10.1007/s11307-021-01580-6
– volume: 54
  start-page: 333
  issue: 3
  year: 2013
  ident: 26199_CR22
  publication-title: J. Nucl. Med.
  doi: 10.2967/jnumed.112.111963
– volume: 98
  start-page: 109
  issue: 1
  year: 2011
  ident: 26199_CR29
  publication-title: Radiother. Oncol.
  doi: 10.1016/j.radonc.2010.10.011
– volume: 11
  start-page: 130
  issue: 1
  year: 2021
  ident: 26199_CR34
  publication-title: EJNMMI Res.
  doi: 10.1186/s13550-021-00871-x
– volume: 180
  start-page: 616
  year: 2004
  ident: 26199_CR17
  publication-title: Strahlenther. Onkol.
  doi: 10.1007/s00066-004-1229-y
– volume: 30
  start-page: 695
  issue: 5
  year: 2003
  ident: 26199_CR24
  publication-title: Eur. J. Nucl. Med. Mol. Imaging
  doi: 10.1007/s00259-002-1096-7
– volume: 50
  start-page: 22
  issue: 1
  year: 2011
  ident: 26199_CR31
  publication-title: Nuklearmedizin
  doi: 10.3413/nukmed-00328-10-07
– volume: 36
  start-page: 417
  issue: 2
  year: 1996
  ident: 26199_CR14
  publication-title: Int. J. Radiat. Oncol. Biol. Phys.
  doi: 10.1016/S0360-3016(96)00325-2
– volume: 11
  start-page: 393
  issue: 6
  year: 2011
  ident: 26199_CR1
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc3064
– volume: 33
  start-page: 2133
  issue: 12
  year: 1992
  ident: 26199_CR7
  publication-title: J. Nucl. Med.
– volume: 49
  start-page: 129s
  issue: Suppl 2
  year: 2008
  ident: 26199_CR25
  publication-title: J. Nucl. Med.
  doi: 10.2967/jnumed.107.045914
– volume: 27
  start-page: 2459
  issue: 9
  year: 2021
  ident: 26199_CR33
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-20-4128
– volume: 54
  start-page: 1370
  issue: 9
  year: 2015
  ident: 26199_CR40
  publication-title: Acta Oncol.
  doi: 10.3109/0284186X.2015.1067721
– volume: 49
  start-page: 6449
  issue: 23
  year: 1989
  ident: 26199_CR39
  publication-title: Cancer Res.
– volume: 54
  start-page: 1543
  year: 2013
  ident: 26199_CR28
  publication-title: J. Nucl. Med.
  doi: 10.2967/jnumed.112.118083
– volume: 17
  start-page: 985
  issue: 5
  year: 1989
  ident: 26199_CR12
  publication-title: Int. J. Radiat. Oncol. Biol. Phys.
  doi: 10.1016/0360-3016(89)90146-6
– volume: 22
  start-page: 199
  issue: 1
  year: 1992
  ident: 26199_CR8
  publication-title: Int. J. Radiat. Oncol. Biol. Phys.
  doi: 10.1016/0360-3016(92)91001-4
– volume: 41
  start-page: 617
  issue: 3
  year: 2021
  ident: 26199_CR35
  publication-title: J. Cereb. Blood Flow Metab.
  doi: 10.1177/0271678X20923857
– volume: 25
  start-page: 365
  issue: 3
  year: 2010
  ident: 26199_CR15
  publication-title: Cancer Biother. Radiopharm.
– volume: 54
  start-page: 201
  issue: 2
  year: 2013
  ident: 26199_CR30
  publication-title: J. Nucl. Med.
  doi: 10.2967/jnumed.112.109330
SSID ssj0000529419
Score 2.416421
Snippet Positron emission tomography (PET)/computed tomography (CT) using the radiotracer 18F-Fluoromisonidazole (FMISO) has been widely employed to image tumour...
Abstract Positron emission tomography (PET)/computed tomography (CT) using the radiotracer 18F-Fluoromisonidazole (FMISO) has been widely employed to image...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 21746
SubjectTerms 631/67/1612
631/67/2321
692/4028/67/1612
692/4028/67/2321
692/700/1421/1771
Atovaquone
Carcinoma, Non-Small-Cell Lung - diagnostic imaging
Carcinoma, Non-Small-Cell Lung - drug therapy
Cell Hypoxia
Computed tomography
Correlation coefficient
Humanities and Social Sciences
Humans
Hypoxia
Hypoxia - diagnostic imaging
Injection
Lung cancer
Lung Neoplasms - diagnostic imaging
Lung Neoplasms - drug therapy
Misonidazole
multidisciplinary
Non-small cell lung carcinoma
Patients
Positron emission tomography
Positron Emission Tomography Computed Tomography
Positron-Emission Tomography - methods
Radioactive tracers
Radiopharmaceuticals
Science
Science (multidisciplinary)
Small cell lung carcinoma
Tomography
Tumors
SummonAdditionalLinks – databaseName: Biological Science Database
  dbid: M7P
  link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELaggMSF9yNQkJG4gbVx7MTxqSpVV5yqPSxSb5Ht2G1QNlmSXUT59XicbKrl0QtSDlHsJE5mPJ6Xv0HoPVdUKOtS4hLNCLeZI8pIRWTO_bhjG2sbh2IT4uwsPz-Xi9Hh1o9plTuZGAR12Rrwkc8S4XVpcCrkR-tvBKpGQXR1LKFxG90BlAQWUvcWk48FolicynGvjL911vv1CvaUeQsMTAdJxN56FGD7_6Zr_pky-VvcNCxH84f_-yGP0INREcXHA-c8Rrds8wTdG0pTXj1FzRLKfV3g1uHLq3X7o1J4cbqcnSxxtQqFjXCoLo5pPieu3rZdu4K8pKpUP9va4qr5GnK8Gn-Gm7Yh_UrVNYYwAa69fMEGuK3DI6xr_wx9mZ8uTz6TsTYDMd7k2ZAstdTZ1GqvERlvXseKCeZiV-aZK7WlwijHyySWzsZMgNtSZFrlJlGca55b9hwd-LfblwiXkmqADYQtuZyVKk-V1zLjUmrKdGpYhOiOQoUZgcuhfkZdhAA6y4uBqoWnahGoWogIfZjuWQ-wHTf2_gSEn3oC5Ha40HYXxTiDC1BunBElEy7h2mltS6Yp8DRVRtg0Qoc7ehejHOiLa2JH6N3U7AkC_1s1tt0Ofbzc5CKO0IuBy6aRsAzgeKh_uNjjv72h7rc01WVACZfeEqRURujjjlOvh_XvX_Hq5q94je4nMHmoP7JDdLDptvYNumu-b6q-extm3y-vnTfc
  priority: 102
  providerName: ProQuest
Title Timing of hypoxia PET/CT imaging after 18F-fluoromisonidazole injection in non-small cell lung cancer patients
URI https://link.springer.com/article/10.1038/s41598-022-26199-7
https://www.ncbi.nlm.nih.gov/pubmed/36526815
https://www.proquest.com/docview/2755009038
https://www.proquest.com/docview/2755578470
https://pubmed.ncbi.nlm.nih.gov/PMC9758119
https://doaj.org/article/0238fc7d37f24bfbbed3b1984e1ac7e5
Volume 12
WOSCitedRecordID wos000934547900062&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: Directory of Open Access Journals (DOAJ)
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: DOA
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: M~E
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVPQU
  databaseName: Biological Science Database
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: M7P
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/biologicalscijournals
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: 7X7
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: BENPR
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Publicly Available Content Database
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: PIMPY
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/publiccontent
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Science Database
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: M2P
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/sciencejournals
  providerName: ProQuest
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3db9MwELdgA4kXxDeBURmJN4gax25sP7KpFTysilCRylNkOzbLlCZTP9C2v56zk5aVzxekyIpixzndnXN3_vgdQm-YIlxZN4pdqmnMbOZiZaSKpWBAd2ITbZOQbIJPp2I-l_mNVF9-T1gHD9wxbuhtijO8pNylTDutbUk18V0RZbgN6KXg9dwIpjpU71QyIvtTMgkVwxVYKn-aDGIvHzTImO9ZogDY_zsv89fNkj-tmAZDNHmA7vceJH7fUf4Q3bLNI3S3yyl59Rg1M5-n6ytuHT67umgvK4Xz8Wx4MsPVImQkwiEtOCZiErt60y7bhd9QVJXquq0trprzsDmrgTvctE28Wqi6xn5-H9fwY8DGq8kS93isqyfo82Q8O_kQ90kVYgOxyjrORpY4O7IaXBkDcXGiKKcucaXIXKkt4UY5VqaJdDah3M838kwrYVLFmGbC0qfoAL5unyNcSqI93p8_S8toqcRIgXuYlFITqkeGRohsGVyYHnHcJ76oi7DyTUXRCaUAoRRBKAWP0NvdOxcd3sZfWx97ue1aeqzs8AA0qOg1qPiXBkXoaCv1oh_AqyLlELr5OSwRode7ahCI57dqbLvp2sAPj_EkQs86JdlRQjOPo0Ogc76nPnuk7tc01VmA95YQwhEiI_Ruq2g_yPozK178D1a8RPdSP0IIXNkROlgvN_YVumO-ravVcoBu8zkPpRigw-PxNP80CMMOytM09yWH8jD_eJp_-Q4H-jIE
linkProvider Directory of Open Access Journals
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwELZKAcGF9yNQwEhwAmvjOImTA0JQumrVstrDIvWW2o7dBmWTZbMFlh_Fb8TjJFstj956QNpDtHGSifONZ8Yez4fQi1BQLrSJiAkkI6GODREqFSRNQiu3r32pfUc2wUej5PAwHW-gn_1eGEir7MdEN1DntYI58kHArS8NkwrJ29kXAqxRsLraU2i0sNjXy282ZGve7H2w3_dlEAx3Jtu7pGMVIMo66wsSR5oaHWlpbbmygaEvGGfGN3kSm1xqypUwYR74qdE-4zDhxmMpEhWIMJRhopm97yV02boRQeJSBcerOR1YNQtp2u3NsaIOGmsfYQ-bjfggVEkJX7N_jibgb77tnymav63TOvM3vPm_ddwtdKNztPG7VjNuow1d3UFXW-rN5V1UTYDO7BjXBp8sZ_X3QuDxzmSwPcHF1BE3YceejmkyJKY8ref1FPKuilz8qEuNi-qzy2Gr7BGu6oo0U1GWGJZBcGnHT6xAm-a4K1vb3EOfLuRl76NN-3T9EOE8pRLKIsKW45DlIomE9aL9PJWUyUgxD9EeEZnqCrMDP0iZuQQBlmQtijKLosyhKOMeerW6ZtaWJTm39XsA2qollBR3f9Tz46wboTJw3oziOeMmCKWRUudMUtBZKhTXkYe2enxl3TjXZGfg8tDz1Wn7QaC_RaXr07aNtQsh9z30oEX1ShIWQ7kham_O1_C-Jur6mao4cVXQUxvpUpp66HWvGWdi_bsrHp3_Fs_Qtd3Jx4PsYG-0_xhdD0Bxqf3FW2hzMT_VT9AV9XVRNPOnTvMxOrpojfkFv6aVkA
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLbGuIgX7pfAACPBE4sax0mcPCAE2yqmoaoPRdqbsR17C0qT0rRA-Wn8OnycpFO57G0PSH2IGidxnO_c7OPzIfQiEoQJbWLfhJL6kU6ML1Qm_CyNbL8DHUgdOLIJNhqlx8fZeAv97PfCQFplrxOdos5rBXPkg5BZXxomFdKB6dIixvvDN7MvPjBIwUprT6fRQuRIr77Z8K15fbhvv_XLMBweTPbe-x3DgK-s477wk1gTo2MtrV1XNkgMBGXUBCZPE5NLTZgSJsrDIDM6oAwm31giRapCEUUySjW1972ELjMoWu7SBsfr-R1YQYtI1u3TgW431lbCfjYb_UHYkvlswxY6yoC_-bl_pmv-tmbrTOHw5v88iLfQjc4Bx29bibmNtnR1B11tKTlXd1E1AZqzE1wbfLqa1d8LgccHk8HeBBdTR-iEHas6JunQN-WyntdTyMcqcvGjLjUuqs8ut62yR7iqK7-ZirLEsDyCS6tXsQIpm-OunG1zD328kJe9j7bt0_VDhPOMSCiXCFuRI5qLNBbWuw7yTBIqY0U9RHp0cNUVbAfekJK7xAGa8hZR3CKKO0Rx5qFX62tmbbmSc1u_A9CtW0KpcfdHPT_hnebi4NQZxXLKTBhJI6XOqSQgy0QopmMP7fRY453-a_gZ0Dz0fH3afhAYb1Hpetm2sfYiYoGHHrQIX_eEJlCGiNibsw3sb3R180xVnLrq6JmNgAnJPLTbS8lZt_49FI_Of4tn6JoVFP7hcHT0GF0PQYaJ_SU7aHsxX-on6Ir6uiia-VOnBDD6dNEC8wuY3p5N
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Timing+of+hypoxia+PET%2FCT+imaging+after+18F-fluoromisonidazole+injection+in+non-small+cell+lung+cancer+patients&rft.jtitle=Scientific+reports&rft.au=Pauline+Bourigault&rft.au=Michael+Skwarski&rft.au=Ruth+E.+Macpherson&rft.au=Geoff+S.+Higgins&rft.date=2022-12-16&rft.pub=Nature+Portfolio&rft.eissn=2045-2322&rft.volume=12&rft.issue=1&rft.spage=1&rft.epage=8&rft_id=info:doi/10.1038%2Fs41598-022-26199-7&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_0238fc7d37f24bfbbed3b1984e1ac7e5
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon